Geoffrey von Maltzahn, Flagship General Partner and co-founder & CEO of Flagship-founded Tessera Therapeutics, explains Tessera's novel gene writing bioplatform and its vast potential for preventing and curing disease.
More from:
Human Health,
Sustainability
Three Questions with Junaid Bajwa, Flagship Senior Partner, Head of UK, and Science Partner for Pioneering Intelligence
The Future of Genetic Medicines is Here
Three Questions with Hari Pujar, Founding President of Mirai Bio and Flagship Operating Partner
Pioneering a Sustainable Future for Food
The Next Generation of Biologics Are Supranatural
Pioneering Profile
